Mid-stage CNS biotech Alto Neuroscience plots $89M IPO

Kyle LaHucik

Biotech Correspondent

Alto Neuroscience joined Fractyl Health in outlining its IPO price range on Monday morning as the two biotechs look to build on the momentum generated …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Mid-stage CNS biotech Alto Neuroscience plots $89M IPO

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

Updated: Trump administration halts more than $750M in funds for Moderna’s bird flu vaccine

PepGen ditches Duchenne programs after mid-stage fail, switches to previously halted muscle wasting therapy

Exclusive: Movement disorder biotech Vima steps onto scene with $60M

Oric locks down cash for Phase 3 prostate cancer trial with early data in hand

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Mid-stage CNS biotech Al­to Neu­ro­science plots $89M IPO

Biotech Correspondent

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Mid-stage CNS biotech Alto Neuroscience plots $89M IPO